Kate Young

Royal Marsden NHS Foundation Trust

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

James Larkin

Royal Marsden NHS Foundation Trust

Lisa Pickering

Royal Marsden NHS Foundation Trust

Samra Turajlic

Royal Marsden NHS Foundation Trust

Fiona Byrne

The Francis Crick Institute

Lewis Au

The Francis Crick Institute

Andrew J.S. Furness

Royal Marsden NHS Foundation Trust

Kim Edmonds

Royal Marsden NHS Foundation Trust

Benjamin Shum

The Francis Crick Institute

Charles Swanton

The Francis Crick Institute

Zayd Tippu

Royal Marsden NHS Foundation Trust

Cooperative Institutions

University College London

207

Royal Marsden Hospital

181

Royal Marsden NHS Foundation Trust

180

The Francis Crick Institute

157

Cancer Research UK

118

Institute of Cancer Research

112

London Cancer

110

CRUK Lung Cancer Centre of Excellence

106

Imperial College London

University College London Hospitals NHS Foundation Trust

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Identification of a nanostring signature that differentiates early pancreatic cancers according to stromal composition and predicts clinical outcome

Annals of Oncology (2019)

Francesco Sclafani Luciano Cascione David Cunningham Kate Young Pietro Carotenuto

Gene signature

10.1093/annonc/mdz156.002

Cite

Citations (0)

Supplementary Tables S1-S8 from Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways

Lavinia Spain Alexander Coulton Irene Lobón Andrew Rowan Désirée Schnidrig

S. Table 1: List of PEACE Consortium members. S. Table 2: Sample database used for the study for Panel, Exome and RNASeq samples. S. Table 3: Overview of lines of treatment given to each patient. S. Table 4: Lesions and patients included in the lesion-level response to ICI analysis. S. Table 5: Hallmark genesets significantly upregulated in normal tissue vs tumor tissue. Table shows p-values for tissue type, purity; T value for tissue type, purity; q-value for tissue type, purity (FDR corrected). S. Table 6: Hallmark genesets significantly upregulated in tumor tissue vs normal tissue. Table shows p-values for tissue type, purity; T value for tissue type, purity; q-value for tissue type, purity (FDR corrected). S. Table 7: Genes included in the target panel. S. Table 8: Tree topology comparisons between manually constructed trees and pairtree-constructed trees.

Table (database)

Tissue sample

Value (mathematics)

10.1158/2159-8290.23283213

Cite

Citations (0)

The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment

Cardio-Oncology (2022)

María Sol Andrés Sivatharshini Ramalingam Stuart D. Rosen John Baksi Rajdeep Khattar

Abstract Background The full range of cardiovascular complications related to the use of Immune checkpoint inhibitors (ICI) is not fully understood. We aim to describe the spectrum of cardiovascular adverse events (cvAEs) by presenting our real-world experience of the diagnosis and management of these complications. Methods Two thousand six hundred and forty-seven (2647) patients were started on ICI treatment between 2014 and 2020. Data from 110 patients referred to the cardio-oncology service with a suspected cvAE was collected prospectively and analysed. Results Eighty-nine patients (3.4%) were confirmed to have cvAEs while on ICI therapy. Myocarditis was the most frequent event (33/89), followed by tachyarrhythmia (27/89), non-inflammatory left ventricular dysfunction (NILVD) (15/89) and pericarditis (7/89). Results from myocarditis and non-inflammatory left ventricular dysfunction cohorts were compared. Myocarditis and NILVD showed significant differences in respect toof troponin elevation, cardiac magnetic resonance abnormalities and ventricular function. Dual ICI therapy and other immune related adverse events were more frequently associated with myocarditis than NILVD. There was a significant difference in the median time from starting ICI treatment to presentation with myocarditis versus NILVD (12 vs 26 weeks p = 0.049). Through early recognition of myocarditis, prompt treatment with steroids and interruption of ICI, there were no cardiovascular in-hospital deaths. NILVD did not require steroid treatment and ICI could be restarted safely. Conclusions The full spectrum of cardiovascular complications in patients with immune checkpoint inhibitors is much broader than initially described. Myocarditis remains the most frequent cvAE related to ICI treatment. A novel type of myocardial injury was observed and defined as Atrial tachyarrhythmias and NILVD were also frequent in this cohort. NILVD has a This differs fromdifferent presentation from ICI-related myocarditis, mainly usually presenting afterby the lack of inflammatory features on CMR and biomarkers and a later presentation in time.

10.1186/s40959-022-00147-w

Cite

Citations (14)

Evolving cardiac biomarkers for immune checkpoint inhibitor related myocarditis in cancer patients

IJC Heart & Vasculature (2023)

Suprateeka Talukder Aruni Ghose Turja Chakraborty Anna Olsson‐Brown Sivatharshini Ramalingam

Immune checkpoint

10.1016/j.ijcha.2023.101278

Cite

Citations (3)

Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer

The Lancet (2022)

Annika Fendler Scott T.C. Shepherd Lewis Au Mary Wu Ruth Harvey

10.1016/s0140-6736(22)00147-7

Cite

Citations (81)

Hyperglycaemia following immune checkpoint inhibitor therapy—Incidence, aetiology and assessment

Diabetic Medicine (2023)

Kaenat Mulla Sheima Farag Benedict Moore Sheila Matharu Kate Young

We systematically studied the presence of hyperglycaemia during treatment with Immune Checkpoint Inhibitors (ICPI) for cancer, in those with and without diabetes at baseline, and determined the cause of new-onset hyperglycaemia, METHODS: Retrospective review of electronic records of those receiving an ICPI for melanoma, lung or renal cancer.Overall, 959 participants were included. In this study, 103 had diabetes at baseline (10.7%). Those with lung cancer had the highest frequency of diabetes; 131 people had hyperglycaemia (defined as at least one glucose ≥11.1 mmol/L) in the year after starting an ICPI. The incidence was 55% in those with diabetes at baseline, and 8.6% in those without baseline diabetes. Among 74 with new-onset hyperglycaemia (without pre-existing diabetes) 76% was attributable to steroid induced diabetes, with 9.5% due to ICPI Induced diabetes resembling type 1 diabetes.Hyperglycaemia is common in persons receiving an ICPI for cancer, including 8.6% of those without known diabetes. While much of this is due to glucocorticoid use, care is needed to avoid missing those with ICPI-induced diabetes who are at risk of diabetic ketoacidosis, which is a medical emergency.

Diabetic ketoacidosis

Ketoacidosis

Etiology

10.1111/dme.15053

Cite

Citations (7)

Abstract A012: Advanced melanoma exhibits a diversity of evolutionary routes to lethality

Cancer Research (2022)

Alexander Coulton Irene Lobón Lavinia Spain Andrew Rowan Desiree Shnidrig

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is available in the Proffered Abstracts section (PR002) of the Conference Proceedings. Citation Format: Alexander Coulton, Irene Lobon, Lavinia Spain, Andrew Rowan, Desiree Shnidrig, Scott Shepherd, Ben Shum, Fiona Byrne, Lewis Au, Kim Edmonds, Ellie Carlyle, Alexandra Renn, Christina Messiou, Charlotte Spencer, Andreas M. Schmidt, Zayd Tippu, Aljosja Rogiers, Max Emmerich, Camille Gerard, Husayn Pallikonda, Cristina Naceur-Lombardelli, Floris Foijer, Hilda van den Bos, René Wardenaar, Diana Spierings, Kate Young, Lisa Pickering, Andrew Furness, Elaine Borg, Miriam Mitchison, David Moore, Mary Falzon, Ian Proctor, Ruby Stewart, Ula Mahadeva, Anna Green, James Larkin, Charles Swanton, Mariam Jamal-Hanjani, Kevin Litchfield, Samra Turajlic. Advanced melanoma exhibits a diversity of evolutionary routes to lethality [abstract]. In: Proceedings of the AACR Special Conference on the Evolutionary Dynamics in Carcinogenesis and Response to Therapy; 2022 Mar 14-17. Philadelphia (PA): AACR; Cancer Res 2022;82(10 Suppl):Abstract nr A012.

Rowan

10.1158/1538-7445.evodyn22-a012

Cite

Citations (0)

Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy

Therapeutic Advances in Medical Oncology (2017)

Emma Kipps Kate Young Naureen Starling

Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease. The majority of patients are diagnosed with locally advanced or metastatic disease with a prognosis of short months. Therapeutic options are limited and until recently, there was no standard second-line chemotherapy option. Liposomal constructs have been engineered to encapsulate chemotherapy thereby preventing premature metabolism, improving distribution and minimizing toxicity. Favourable preclinical data on liposomal irinotecan and early phase trials, led to a recently published phase III trial of liposomal irinotecan in combination with fluorouracil and folinic acid in patients with metastatic PDAC, who progressed after gemcitabine-based chemotherapy. As a direct result, the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) have approved the use of liposomal irinotecan in this setting. However, first-line treatment options for this disease now include the combination regimen, FOLFIRINOX, in patients with good performance status, and the role of second-line combination treatment with liposomal irinotecan in this setting is unclear. Recent advances have changed the therapeutic landscape, as clinicians are now able to choose a sequential approach to treatment tailored to the individual patient characteristics. This article reviews current treatment options for metastatic PDAC and focuses on the efficacy, safety and place in therapy of liposomal irinotecan.

FOLFIRINOX

Regimen

10.1177/1758834016688816

Cite

Citations (28)

Cytokine release syndrome in a patient with colorectal cancer following vaccination with BNT162b2 (tozinameran)

Research Square (Research Square) (2021)

Samra Turajlic Lewis Au Annika Fendler Scott Shepherd Karolina Rzeniewicz

Abstract We present a case of cytokine release syndrome (CRS) that occurred five days after vaccination with BTN162b2 (tozinameran), an mRNA COVID-19 vaccine, in a patient with colorectal cancer on long-standing anti-PD-1 monotherapy. The CRS was evidenced by raised inflammatory markers, thrombocytopenia, elevated cytokine levels (IFN-y/IL-2R/IL-18/IL-16/IL-10), and steroid responsiveness.

10.21203/rs.3.rs-355230/v1

Cite

Citations (0)

Figure 6 from Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways

Lavinia Spain Alexander Coulton Irene Lobón Andrew Rowan Désirée Schnidrig

Identification of a likely non–whole-genome–doubled clone that was not identifiable from bulk sequencing data in CRUKP2567. Clonal phylogeny of CRUKP2567 (A), with anatomic diagram (B) based on bulk SNVs mapping samples to clones on the tree. The scale indicates the number of mutations. C, MEDICC2 copy-number tree for bulk exome samples from CRUKP2567. The cluster highlighted in blue has undergone one WGD event, while the other nonhighlighted cluster, containing brain metastasis and primary tumor samples, has not. Diamonds indicate the samples for which bulk copy-number profiles are displayed in Supplementary Fig. S23. D, Hierarchical clustering tree containing all single cells (SS) from FACs-high-ploidy sorting (FH) and FACs-low-ploidy sorting (FL), as well as WGD bulk samples and non-WGD bulk samples. E, Radiologic images of the patient indicating thorax upon initiation of stage IV disease and complete extracranial response to BRAF inhibitor, followed by rapid recolonization of the thorax with resistant clones (left to right). BR, brain; BRAFi, BRAF inhibitor; CR, complete response; DI, diaphragm; LN, lymph node; LU, lung; MEKi, MEK inhibitor; PC, pericardium, PLFa, pleural fluid (archival); PR, primary.

10.1158/2159-8290.23283222

Cite

Citations (0)